We’re thrilled to announce this exciting news in cancer innovation: Tubulis has inked its second major deal this year! As part of the deal, Tubulis out-licenses the Antibody-Drug Conjugate TEQ102 (formerly TUB-010) to Oncoteq, a Switzerland based biotech company focused on innovative cancer medications.
TEQ102 is a potential best-in-class treatment for CD30 positive Lymphomas, which includes among others T-Cell and Hodgkin Lymphomas. The ADC was developed based on Tubulis innovative TubTag® linker technology, which allows for a highly selective and reliable delivery of cytotoxic agents to CD-30 expressing cancer cells.
TEQ102’s unique properties could enable higher and more effective doses, paving the way for long-term treatments and significantly improving outcomes and quality of life for patients. The IND-ready drug candidate will target a market projected to exceed USD 3 billion within the coming years.
We congratulate the whole Team of Tubulis for achieving this great deal!
More information in the press release under the following Link
More about Tubulis
